Phase III results of PRT 4445 (andexanet alfa) as an antidote were published in the New England Journal of Medicine- Portola Pharmaceuticals

Portola Pharmaceuticals announced that the results of its Phase III ANNEXA study of PRT 4445 (andexanet alfa) as an antidote to Factor Xa inhibitors were published online by The New England Journal of Medicine. ANNEXA-R and ANNEXA-A evaluated the safety and efficacy of andexanet alfa, an investigational reversal agent. Results showed that both ANNEXA Part 1 (bolus only) and Part 2 (bolus plus continuous infusion) met all primary and secondary efficacy endpoints, including the measurement of reversal Anti-Xa activity (p<0.0001) for both rivaroxaban (Xarelto) and apixaban (Elequis).